Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor - Concepedia

Concepedia

Publication | Open Access

Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor

DOI Full Paper Access

46

Citations

38

References

2021

Year

Rong Hu, Wanli Wang, Ying-Yue Yang, Xia-Tong Hu, Qiwei Wang, Weiqiong Zuo, Ying Xu, Qiang Feng, Ningyu Wang

European Journal of Medicinal Chemistry

UrologyOncologyGenitourinary CancerMedicineSelective Brd4 ProtacDual Bet/plk1 InhibitorAnti-cancer AgentTumor SuppressorProstatic DiseaseAr-positive Prostate CancerPharmacology

References

	Year	Citations

Page 1

Page 1